Oramed Pharmaceuticals Inc. (ORMP)
Largest Insider Buys in Sector
ORMP Stock Price History Chart
ORMP Stock Performance
About Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a …
Insider Activity of Oramed Pharmaceuticals Inc.
Over the last 12 months, insiders at Oramed Pharmaceuticals Inc. have bought $0 and sold $0 worth of Oramed Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Oramed Pharmaceuticals Inc. have bought $415,102 and sold $1.8M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,800 shares for transaction amount of $8,398 was made by Mayer Arie (director) on 2023‑04‑04.
List of Insider Buy and Sell Transactions, Oramed Pharmaceuticals Inc.
| 2023-04-04 | director | 3,800 0.01% | $2.21 | $8,398 | +30.56% | |||
| 2023-04-03 | director | 5,009 0.0129% | $2.22 | $11,120 | +27.60% | |||
| 2023-03-16 | President and CEO | 26,000 0.0615% | $2.04 | $53,014 | +23.98% | |||
| 2023-03-14 | Sale | Chief Scientific Officer | 100,000 0.2466% | $2.01 | $201,000 | +28.71% | ||
| 2023-03-14 | President and CEO | 100,000 0.2466% | $2.01 | $201,000 | +28.71% | |||
| 2023-03-14 | director | 50,000 0.1257% | $2.05 | $102,450 | +28.71% | |||
| 2023-03-13 | director | 20,000 0.0499% | $1.96 | $39,120 | +33.83% | |||
| 2023-01-03 | Sale | Chief Commercial Officer | 13,325 0.0346% | $12.55 | $167,195 | -81.41% | ||
| 2022-03-21 | Sale | 10,000 0.0258% | $9.41 | $94,096 | -28.66% | |||
| 2021-11-01 | Sale | director | 3,000 0.0084% | $25.60 | $76,800 | -65.71% | ||
| 2021-09-16 | Sale | director | 21,100 0.0579% | $20.99 | $442,830 | -55.94% | ||
| 2021-08-09 | Sale | President and CEO | 220,000 0.7367% | $20.11 | $4.42M | -50.47% | ||
| 2019-09-09 | director | 50,000 0.2901% | $2.92 | $146,000 | +20.49% | |||
| 2019-07-18 | director | 8,994 0.0501% | $3.85 | $34,672 | -15.66% | |||
| 2019-07-17 | director | 60,040 0.3268% | $3.63 | $218,118 | -12.57% | |||
| 2019-07-16 | director | 40,000 0.2278% | $3.52 | $140,878 | -5.65% | |||
| 2019-07-11 | director | 2,640 0.0147% | $3.22 | $8,501 | +1.21% | |||
| 2018-08-09 | director | 5,000 0.029% | $4.95 | $24,740 | -25.77% | |||
| 2018-07-11 | President and CEO | 244 0.0014% | $5.92 | $1,444 | -36.64% | |||
| 2018-07-10 | Sale | President and CEO | 122 0.0007% | $5.98 | $730 | -36.67% |
Insider Historical Profitability
| Bronfeld Zeev | 10 percent owner | 5808517 14.4089% | $2.37 | 1 | 1 | |
| REGALS CAPITAL MANAGEMENT LP | 10 percent owner | 1453637 3.606% | $2.37 | 7 | 0 | <0.0001% |
| Sank Leonard | director | 374999 0.9302% | $2.37 | 12 | 0 | +53.34% |
| Li Xiaopeng | director | 206350 0.5119% | $2.37 | 2 | 0 | +13.29% |
| KIDRON NADAV | President and CEO | 126000 0.3126% | $2.37 | 7 | 2 | +24.17% |
Institutional Investor Ownership
| Murchinson Ltd | $4.03M | 3.4 | 1.38M | +31.38% | +$962,125.30 | 0.45 | |
| Bml Capital Management Llc | $2.47M | 2.08 | 844,496 | -33.06% | -$1.22M | 1.89 | |
| Boothbay Fund Management LLC | $2.01M | 1.7 | 689,749 | +31.38% | +$481,064.14 | 0.07 | |
| Susquehanna International Group | $1.01M | 0.85 | 344,438 | +650.15% | +$871,684.28 | <0.01 | |
| Rathbone Brothers | $846,225.00 | 0.71 | 289,803 | 0% | +$0 | 0.01 |